Neurogene Inc. valuation and forecast
Explore the models for Neurogene Inc., adjust their assumptions and compare your own valuation with the platform's.
Stock price today
Loading chart…
Third-party market data · may be delayed
Model estimate per share
Not valued: the figures our models need are missing or failed our data-quality checks.
Price vs value
No model value: limited reported history: available models are shown without a Buy/Hold/Sell rating. How we value companies.
Your valuation workspace
What is NGNE worth to you?
Start with the company's financial data. Make the assumptions your own.
01 / Assumptions
Follow the forecast
The cash flows behind your value
View annual figures
| Forecast year | Cash flow / share |
|---|
Negative cash flows are shown in terracotta. Before the terminal value and equity bridge. Residual-income models show excess earnings; dividend models show dividends.
See the range of possibilities
Compare and combine your models
Weights start with the platform's included models. Change them to build your own combination. Select a model name to edit its assumptions.
| Model | Your value / share | Weight |
|---|
The platform's price and consistency filters are not reapplied to your scenarios.
Other model types 22 unavailable for NGNE
Price-to-earnings vs peers
no twelve-month earnings or share count in the filings yet
Residual income
no twelve-month earnings or share count in the filings yet
Justified price-to-book
no twelve-month earnings or share count in the filings yet
Revenue-to-maturity model
revenue and margins don't support a positive value
Price-to-sales vs peers
no twelve-month earnings or share count in the filings yet
Cash-flow DCF
This model does not apply to this company with the available financial data.
Growth DCF
This model does not apply to this company with the available financial data.
P/B vs return on equity
This model does not apply to this company with the available financial data.
Peer price-to-book
This model does not apply to this company with the available financial data.
Peer price-to-FFO
This model does not apply to this company with the available financial data.
Forward peer P/E
This model does not apply to this company with the available financial data.
Forward peer price-to-sales
This model does not apply to this company with the available financial data.
P/E comparison
This model does not apply to this company with the available financial data.
P/S comparison
This model does not apply to this company with the available financial data.
PEG comparison
This model does not apply to this company with the available financial data.
Two-stage dividend discount
This model does not apply to this company with the available financial data.
Growing-dividend model
This model does not apply to this company with the available financial data.
REIT funds from operations
This model does not apply to this company with the available financial data.
Utility earnings
This model does not apply to this company with the available financial data.
Book value / net assets
This model does not apply to this company with the available financial data.
Reported crypto treasury NAV
This model does not apply to this company with the available financial data.
Proved-reserve NAV
This model does not apply to this company with the available financial data.
Model values are estimates under the assumptions shown. They are not share-price forecasts or investment advice.
Analyst recommendations
Monthly trend
- Oct 202610
- Sep 20269
- Aug 20269
Counts of recommendations published by analysts covering Neurogene Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.
Price history
Loading chart…
Third-party market data · may be delayed
NGNE valuation questions
- How does Fundamentalytics value Neurogene Inc.?
- We use the models that fit Neurogene Inc.'s business and available financial data. Each model has its own assumptions and data requirements. The calculator explains which models are available and lets you adjust their inputs.
Data: SEC EDGAR filings, retrieved Invalid Date. Method: how we value companies. Disclosures: research and recommendations disclosure. Back to Neurogene Inc.